Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
NEW YORK August 4, 2025 Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
Emphasis is placed on protecting-group selection, step economy, and preparative feasibility as discussed in peer-reviewed organic chemistry research
Researchers believe that these medications may influence blood sugar and hydration levels, both of which are common migraine triggers
A common pattern (exact brands and steps vary): Semaglutide: start low for 4 weeks, then step up every 4+ weeks toward a target dose if tolerated
US$ 22.22
US$ 25.27
US$ 24.78
US$ 29.65
US$ 24.08
